SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $185,685,956 |
| Positions | 10 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Bicara Therapeutics Inc. | BCAX | Common Stock | $54,099,634 | 1,822,150 |
| Nuvation Bio Inc. | NUVB | Common Stock Class A | $45,900,586 | 8,081,089 |
| Kestra Med Technologies Ltd | KMTS | Common Stock | $26,003,471 | 1,022,149 |
| BridgeBio Oncology Therapeutics Inc. | BBOT | Common Stock | $25,067,217 | 3,289,661 |
| Beta Bionics Inc. | BBNX | Common Stock | $20,624,588 | 1,316,183 |
| Alumis Inc. | ALMS | Common Stock | $6,788,916 | 241,255 |
| Sana Biotechnology, Inc. | SANA | Common Stock | $2,944,688 | 843,750 |
| ImageneBio, Inc. | IMA | Common Stock | $2,686,630 | 455,361 |
| enGene Holdings Inc. | ENGN | Common Stock | $1,516,098 | 876,357 |
| Odyssey Therapeutics Inc. | ODTX | Common Stock | $54,128 | 2,893 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.